 |
|
Why cisplatin kills breast cancer cells when other drugs fail
April 20, 2007The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2. Individuals with such breast cancer (known as triple-negative breast cancer) do not respond to treatment with commonly used chemotherapeutic drugs and their prognosis is relatively poor. But now, a new study from researchers at Massachusetts General Hospital Cancer Center, Boston, has indicated that triple-negative breast cancer cell lines are sensitive to exposure to the chemotherapeutic cisplatin.
In the study, which appears online on April 19 in advance of publication in the May print issue of the Journal of Clinical Investigation, Leif Ellisen and colleagues show that triple-negative breast cancer specimens express increased amounts of two proteins, delta-Np63 and TAp73. Delta-Np63 was shown to bind TAp73 and prevent it from killing the cancerous cells. Importantly, the chemotherapeutic drug cisplatin, but not other commonly used chemotherapeutic drugs, was found to release TAp73 from delta-Np63, causing the cells to be killed. This study indicates that individuals with triple-negative breast cancer might benefit from early treatment with cisplatin if their cancerous cells express increased amounts of delta-Np63 and TAp73.
Journal of Clinical Investigation
Cisplatin Current Events and Cisplatin News RSSStudy of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.
Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.
Study supports DNA repair-blocker research in cancer therapy
Scientists at Dana-Farber Cancer Institute have uncovered the mechanism behind a promising new approach to cancer treatment: damaging cancer cells' DNA with potent drugs while simultaneously preventing the cells from repairing themselves.
New cancer drug delivery system is effective and reversible
For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.
Nanoparticle-delivered 'suicide' genes slowed ovarian tumor growth
Nanoparticle delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect this therapy could be tested in humans within 18 to 24 months, according to a report in Cancer Research, a journal of the American Association for Cancer Research.
Therapeutic delivery of a gene to dysfunctional nerves
Medical conditions that affect sensory nerves outside the brain and spinal cord are known as sensory neuronopathies. These conditions, which are extremely painful, include shingles and can be caused by anticancer drugs such as cisplatin.
Defeating nicotine's double role in lung cancer
A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.
miR-196a promotes the metastases of tumors
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins.
UNC study supports role of circadian clock in response to chemotherapy
For years, research has hinted that the time of day that cancer patients receive chemotherapy can impact their chances of survival. But the lack of a clear scientific explanation for this finding has kept clinicians from considering timing as a factor in treatment.
Team finds breast cancer gene linked to disease spread
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death.
More Cisplatin Current Events and Cisplatin News Articles
 |
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug by Bernhard Lippert (Editor) 30 years after its discovery as an antitumor agent, cisplatin represents today one of the most successful drugs in chemotherapy. This book is intended to reminisce this event, to take inventory, and to point out new lines of development in this field. Divided in 6 sections and 22 chapters, the book provides an up-to-date account on topics such as - the chemistry and biochemistry of cisplatin, - the clinical status of Pt anticancer drugs, - the impact of cisplatin on inorganic and coordination chemistry, - new developments in drug design, testing and delivery. It also includes a chapter describing the historical development of the discovery of cisplatin. The ultimate question - How does cisplatin kill a cell? - is yet to be answered, but there are now... |
 |
Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References by ICON Health Publications (Author) In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. |
 |
Revivin by Chi Enterprise Revivin is designed to benefit cancer and symptoms of poor immunity. Clinical studies in human tumor cells compared Revivin to the most popular chemotherapy agents, showing the following results for colon, breast, and liver cancer: Revivin is more sensitive than Vincristin and Mytomycin. For colon and liver, Revivin is more sensitive than 5-Fu. For breast and cervical, Revivin is more sensitive that Cis-Platin. Revivin is non-toxic and, unlike chemotherapy, has NO side effects. It also helps reduce pain and inflammation, helps stop bleeding, and is good for stomach functions. |
|
The Mechanism of Cisplatin Resistance and Its Circumvention by Yoshihiro Kikuchi (Editor) | |
![Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants [An article from: DNA Repair]](http://ecx.images-amazon.com/images/I/51FZ3K9Y7XL._SL160_.jpg) |
Cisplatin induces DNA double-strand break formation in Escherichia coli dam mutants [An article from: DNA Repair] by A. Nowosielska (Author), M.G. Marinus (Author) This digital document is a journal article from DNA Repair, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Escherichia coli dam cells are more susceptible to the cytotoxic action of cisplatin than wildtype. Dam mutS or dam mutL bacteria, however, are resistant to this agent indicating that active mismatch repair sensitizes dam cells to cisplatin toxicity. Genetic data, obtained previously, were consistent with the generation and repair of cisplatin-induced double-strand breaks (DSBs). We measured DSB formation in temperature-sensitive dam recB mutants, after exposure to cisplatin, using pulse field gel electrophoresis and observed... |
![Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation [An article from: Mut.Res.-Genetic Toxicology and Environmental Mutagenesis]](http://ecx.images-amazon.com/images/I/51VRJGWFK9L._SL160_.jpg) |
Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation [An article from: Mut.Res.-Genetic Toxicology and Environmental Mutagenesis] by S.M. Cherry (Author), P.A. Hunt (Author), T.J. Hassold (Author) This digital document is a journal article from Mut.Res.-Genetic Toxicology and Environmental Mutagenesis, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Meiotic recombination is initiated by a series of double-strand breaks (DSBs) in areas of the genome that generally contain promoters and feature an open chromatin configuration [T.D. Petes, Meiotic recombination hot spots and cold spots, Nat. Rev. Genet. 2 (2001) 360-369]. To investigate whether induced DSBs likewise lead to recombinational repair and whether the placement of new exchange events alters normal patterns of recombination, we used the chemotherapeutic drug... |
|
Gale Encyclopedia of Cancer: Cisplatin by RPh., BCOP Nancy J. Beaulieu (Author) The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements: Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include... | |
|
Effect of Cassia auriculata Linn. Root extract on cisplatin and gentamicin-induced renal injury.: An article from: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology by S. Annie (Author), P.L. Rajagopal (Author), S. Malini (Author) This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Thomson Gale on August 1, 2005. The length of the article is 3558 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Effect of Cassia auriculata Linn. Root extract on cisplatin and gentamicin-induced renal injury. Author: S. Annie Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Magazine/Journal) Date: August 1, 2005 Publisher: Thomson Gale Volume: 12 Issue: 8 Page: 555(6) Distributed by... | |
|
Cisplatin: Current Status and New Developments by A.W. Prestayko (Editor), etc. (Editor) | |
|
MVAC Regimen, Cystectomy Add Life in Bladder Ca.(methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of metastatic bladder cancer): An article from: Internal Medicine News by Timothy F. Kirn (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on July 15, 2001. The length of the article is 328 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: MVAC Regimen, Cystectomy Add Life in Bladder Ca.(methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of metastatic bladder cancer) Author: Timothy F. Kirn Publication: Internal Medicine News (Magazine/Journal) Date: July 15, 2001 Publisher: International Medical News Group Volume: 34 Issue: 14 Page: 4 Distributed by Thomson... |
| © 2009 BrightSurf.com |